Literature DB >> 22399220

Staphylococcus aureus, including community-acquired methicillin-resistant S. aureus, in a level III NICU: 2001 to 2008.

Divya Rana1, Nazha Abughali, Deepak Kumar, Dennis M Super, Michael R Jacobs, Mary L Kumar.   

Abstract

OBJECTIVE: To determine epidemiology and clinical characteristics of infants with methicillin-susceptible (MSSA) and -resistant Staphylococcus aureus (MRSA) in a level III neonatal intensive care unit (NICU). STUDY
DESIGN: All NICU admissions (2001 to 2008) with any positive S. aureus culture were included as cases. Cases were further characterized as either colonized or infected with invasive disease.
RESULTS: Four thousand three hundred four infants were admitted; 273 (6.3%) had at least one culture positive for S. aureus, including 198 with MSSA and 75 with MRSA. Invasive disease occurred in 23.2% of MSSA cases versus 29.3% MRSA (p = 0.298). Between the study periods 2001 to 2005 versus 2006 to 2008, the incidence of all MSSA cultures (colonization and invasive disease) decreased from 53.6 to 38.9/1000 admissions (p = 0.044), and that of MRSA increased from 13.7 to 24.77/1000 admissions (p = 0.010). The incidence of invasive MSSA (p = 0.49) and MRSA (p = 0.38) disease between the two periods remained similar. Infants with invasive MRSA versus MSSA had a longer duration of positive cultures (55 versus 19 days, p = 0.009). None of five available isolates collected prior to 2006 was characterized as USA300, but 11/21 isolates collected subsequently were USA300 (p = 0.053).
CONCLUSION: The incidence of MRSA (colonization and infection) nearly doubled during the study period coinciding with emergence of community-acquired MRSA USA300.
Copyright © 2012 Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2012        PMID: 22399220     DOI: 10.1055/s-0032-1304819

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  7 in total

Review 1.  New Threats from an Old Foe: Methicillin-Resistant Staphylococcus aureus Infections in Neonates.

Authors:  Ying Dong; Kirsten Glaser; Christian P Speer
Journal:  Neonatology       Date:  2018-05-25       Impact factor: 4.035

2.  Epidemiological Evaluation of Blood Culture Patterns among Neonates Receiving Vancomycin.

Authors:  Salman Y Yakub; Jonathan E Constance; Chris Stockmann; Matthew Linakis; Sarah C Campbell; Catherine M T Sherwin; Ernest K Korgenski; Alfred Balch; Michael G Spigarelli
Journal:  Indian J Microbiol       Date:  2014-06-17       Impact factor: 2.461

3.  Update on Epidemiology and Treatment of MRSA Infections in Children.

Authors:  Michael Z David; Robert S Daum
Journal:  Curr Pediatr Rep       Date:  2013-09-01

Review 4.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

5.  A Neonatal Murine Model of MRSA Pneumonia.

Authors:  Elizabeth A Fitzpatrick; Dahui You; Bishwas Shrestha; David Siefker; Vivek S Patel; Nikki Yadav; Sridhar Jaligama; Stephania A Cormier
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

6.  Survival Benefit of Empirical Therapy for Staphylococcus aureus Bloodstream Infections in Infants.

Authors:  Joshua T Thaden; Jessica E Ericson; Heather Cross; Stephen P Bergin; Julia A Messina; Vance G Fowler; Daniel K Benjamin; Reese H Clark; Christoph P Hornik; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2015-11       Impact factor: 3.806

7.  Bacterial invasive infections in a neonatal intensive care unit: a 13 years microbiological report from an Italian tertiary care centre.

Authors:  M Mariani; R Bandettini; D LA Masa; D Minghetti; I Baldelli; S Serveli; A Mesini; C Saffioti; L A Ramenghi; E Castagnola
Journal:  J Prev Med Hyg       Date:  2020-07-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.